Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

CHARM Chemometric histopathology via coherent Raman imaging for precision medicine

Coordinator
Cambridge Raman Imaging SRL, Italy
Runs
1 May 2022 to 31 October 2025
Status
Running
EU funding
€2.4m
Total cost
€2.4m
Partners
7 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101058004

What the project is doing

In the project's own words, from its summary on CORDIS.

The CHARM project aims to radically transform the cancer diagnosing process and bring the emerging field of digital histopathology to the next level, introducing a novel technology for tissue analysis, capable to measure the molecular composition of the patient tissue samples and to recognize and classify the tumor in a completely label/stain-free way. The instrument, integrated with artificial intelligence (AI), will offer to histopathologists a reliable, fast and low-cost Clinical Decision Support System (CDSS) for cancer diagnosis and personalized cancer therapy.

We will develop a Class C, (IVDR, In-Vitro Diagnostic Regulation) medical device consisting of a turnkey low-cost broadband Coherent Raman Scattering (CRS) microscope (enabled by our patented graphene-based fiber laser technology), named the Chemometric Pathology System (CPS), integrating an AI module based on deep learning, statistics and machine learning. The CPS will be capable of automatically analyzing unstained tissues, providing fast and accurate tumour identification (differentiating normal vs neoplastic tissues) with accuracy >98% and final tumour diagnosis prediction (differentiating and grading histologic subtypes) with accuracy >90%, thus offering to the histopathologist a decision tree compatible with existing clinical protocols but with biomolecular-based objectivity and reduced time to result (TRL6).

We will develop a robust business case for the application and ensure the project continuation to higher TRLs and the final market entrance. This proposal builds on the results of the ERC POC project GSYNCOR.

Topics

Who is involved

OrganisationCityCountryRole
Cambridge Raman Imaging SRLVeronaItalyCoordinator
Universitatsklinikum JenaJenaGermanyParticipant
Inspiralia Sociedad LimitadaMadridSpainParticipant
Consiglio Nazionale Delle RicercheRomaItalyThird party
In SRLUdineItalyThird party
Politecnico Di MilanoMilanoItalyParticipant
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI